Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference19 articles.
1. EMA. Summary of opinion (initial authorisation). Eklira Genuair: aclidinium bromide. European Medicines Agency, Committee for Medicinal Products for Human Use; 24 May 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002211/WC500127779.pdf. Accessed 3 Feb 2014.
2. EMA. Summary of opinion (initial authorisation). Duaklir Genuair: aclidinium bromide/ formoterol fumarate dihydrate. European Medicines Agency, Committee for Medicinal Products for Human Use; 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003745/WC500173689.pdf. Accessed 7 May 2018.
3. Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013;33(12):893–904. https://doi.org/10.1007/s40261-013-0138-1.
4. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830–6. https://doi.org/10.1183/09031936.00225511.
5. Kerwin EM, D’Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90–101. https://doi.org/10.3109/15412555.2012.661492.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献